Review Article

Advancements in AAV Therapy: A Bright Future for Cartilage Regeneration in Arthritis Treatment

Abstract

Arthritis is a debilitating condition affecting millions of individuals worldwide, characterized by joint inflammation and cartilage damage. Current treatment options provide some relief of symptoms, but do not address the underlying cause of the disease and may have significant side effects. AAV-based gene therapy represents a promising approach to the treatment of arthritis by promoting the regeneration of cartilage and reducing inflammation in the affected joints. AAV vectors can be engineered to deliver genes that promote the production of chondrocytes, the cells that produce cartilage. However, several challenges need to be addressed in order to fully realize the potential of AAV-based gene therapy, including the development of targeted delivery approaches, optimization of vector design, and the need to overcome vector immunity. Additionally, the use of cartilage-specific promoters and combination therapy may help overcome these challenges and advance the development of AAV-based gene therapy for arthritis. Further research in this field has the potential to significantly improve the lives of individuals affected by this debilitating condition.

Comment [51]: Please state the full form in the beginning

Keywords: arthritis, AAV therapy, cartilage regeneration

Introduction

Arthritis is a chronic, degenerative disease affecting millions of people worldwide, and is one of the leading causes of disability in the elderly population (CDC, 2020). Arthritis is an umbrella term that encompasses a number of different conditions, including osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA), among others. OA is the most common form of arthritis and is characterized by the loss of articular cartilage, resulting in joint pain, stiffness, and disability (Martel-Pelletier & Pelletier, 2016). RA and PsA, on the other hand, are autoimmune diseases characterized by chronic inflammation of the synovial membrane, which leads to joint destruction and disability if left untreated (Smolen et al., 2016; Ritchlin& Colbert, 2018). Despite the wide range of arthritis subtypes and associated symptoms, current treatment options for arthritis are largely focused on symptom management and do not offer a cure.

In recent years, gene therapy has emerged as a promising approach for treating arthritis, particularly for conditions such as OA where the loss of articular cartilage is a key factor in the pathogenesis of the disease (Luo et al., 2020). Gene therapy involves the delivery of therapeutic genes to target cells or tissues, with the aim of restoring or augmenting normal cellular function (Merten et al., 2019). Adeno-associated virus (AAV) vectors have become a popular choice for gene therapy due to their safety, high efficiency of transduction, and the ability to target specific cell types (Wang et al., 2021). AAV vectors are non-pathogenic and non-replicative, making

them a safe choice for clinical applications. Furthermore, the ability to engineer AAV vectors to target specific cell types and to regulate gene expression has made them a versatile tool for gene therapy.

In the context of arthritis, one of the major goals of gene therapy is to promote cartilage regeneration. Cartilage regeneration is a complex process involving a number of different cell types and molecular signals, and it has been challenging to develop effective therapeutic strategies for promoting cartilage regeneration in vivo (Gao et al., 2018). However, recent studies have shown that AAV vectors can be used to deliver genes that promote the differentiation of chondrocytes, the cells responsible for producing cartilage, and that this approach can lead to improved cartilage repair and reduced pain in preclinical models of OA (Luo et al., 2020; Liu et al., 2020).

Despite the promising results obtained in preclinical studies, significant challenges remain in optimizing the design and delivery of AAV vectors for cartilage regeneration in humans. Factors such as vector serotype, route of delivery, and dosing regimen can all affect the efficacy of AAV-mediated gene therapy (Kaeppel et al., 2019). In addition, the safety and ethical considerations associated with gene therapy, including the potential for immune responses and off-target effects, need to be carefully evaluated. The purpose of this study is to investigate the potential of AAV vectors for promoting cartilage regeneration in OA and to explore the design and delivery factors that affect their efficacy in preclinical models.

II. Current Treatment Options for Arthritis

Arthritis is a chronic disease that affects millions of people worldwide, and can cause significant pain and disability. While there is no cure for arthritis, there are a variety of treatment options available that can help manage symptoms and slow down the progression of the disease.

A. Symptom Management

Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs are a common first-line treatment for arthritis pain and inflammation. They work by blocking the production of prostaglandins, which are chemicals that cause inflammation and pain. NSAIDs can be taken orally or applied topically, and include drugs such as aspirin, ibuprofen, and naproxen (Singh et al., 2018). However, long-term use of NSAIDs can have side effects, including gastrointestinal bleeding and increased risk of cardiovascular disease (Trelle et al., 2011).

Corticosteroids: Corticosteroids are powerful anti-inflammatory drugs that can be injected directly into the affected joint or taken orally. They are typically used for short-term symptom management due to their potential side effects, including weight gain, osteoporosis, and increased risk of infection (Conaghan et al., 2019). In addition, corticosteroids can have a negative impact on bone health, leading to decreased bone density and increased risk of fractures (Waljee et al., 2018).

Disease-modifying antirheumatic drugs (DMARDs): DMARDs are a class of drugs used to treat autoimmune forms of arthritis, such as rheumatoid arthritis and psoriatic arthritis. They work by suppressing the immune system and reducing inflammation. DMARDs can be taken orally or by

injection, and include drugs such as methotrexate, sulfasalazine, and biologic agents (Smolen et al., 2017). While DMARDs can be effective in reducing inflammation and slowing down joint damage, they can also have significant side effects, including increased risk of infection and liver toxicity (Emery et al., 2014).

B. Physical Therapy and Lifestyle Changes

Physical therapy: Physical therapy can help improve joint function, reduce pain, and increase range of motion. Techniques such as massage, exercise, and heat or cold therapy may be used to relieve arthritis symptoms (Dziedzic et al., 2020). Physical therapy can also help improve overall fitness and reduce the risk of falls, which can be a particular concern for older adults with arthritis (Patel et al., 2018).

Weight management: Excess weight puts additional stress on the joints, particularly the knees and hips. Losing weight can help reduce pain and improve joint function in people with arthritis (Messier et al., 2013). In addition, weight loss can have other health benefits, including reduced risk of cardiovascular disease and diabetes (Stefan et al., 2018).

Joint protection: Avoiding activities that put undue stress on the joints, using assistive devices such as canes or braces, and modifying the home environment can all help protect the joints and reduce pain (Loew et al., 2019). For example, using ergonomic tools such as cushioned mats and grip-enhancing utensils can make daily tasks easier and reduce strain on the joints.

While current treatments for arthritis can be effective in managing symptoms and improving joint function, there is still a need for more targeted and effective therapies, particularly for conditions such as osteoarthritis where there is a loss of cartilage. Gene therapy using AAV vectors has shown promise in preclinical studies for promoting cartilage regeneration and may offer a novel approach for treating arthritis

III. Gene Therapy for Arthritis

Current treatments for arthritis are largely focused on managing symptoms and slowing down disease progression, but do not address the underlying cause of the disease. Gene therapy, on the other hand, offers a potentially curative approach by targeting the root cause of the disease.

Gene therapy involves the delivery of genetic material to cells in the body to alter their function or produce therapeutic proteins. One promising approach for gene therapy in arthritis is the use of adeno-associated virus (AAV) vectors to deliver genes that promote cartilage regeneration.

A. Mechanisms of AAV Vectors

AAV vectors are small, non-pathogenic viruses that have been widely used in gene therapy due to their safety and efficacy (Kaeppel et al., 2019). AAV vectors are able to infect a wide range of cell types, including non-dividing cells, and integrate their genetic material into the host cell's genome. This allows for stable, long-term expression of the delivered gene (Merten et al., 2019).

AAV vectors have been shown to be safe in several clinical trials for various diseases, including hemophilia and spinal muscular atrophy (Mingozzi& High, 2011).

B. Preclinical Studies

Using AAV Vectors for a~~A~~rthritis,s~~S~~everal preclinical studies have shown promise for the use of AAV vectors in promoting cartilage regeneration in arthritis. For example, Liu et al. (2020) demonstrated that AAV-mediated overexpression of follistatin-like protein 1 (FSTL1) promoted cartilage repair in a mouse model of osteoarthritis. FSTL1 is a protein that has been shown to stimulate chondrocyte proliferation and differentiation, and promote extracellular matrix synthesis (Wang et al., 2019). Similarly, Luo et al. (2020) showed that AAV-mediated transfer of a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) enhanced chondrogenesis and inhibited the progression of osteoarthritis in mice. ADAMTS5 is an enzyme that degrades cartilage extracellular matrix, and overexpression of ADAMTS5 inhibitors has been shown to promote cartilage repair in preclinical studies (Stanton et al., 2005).

C. Clinical Trials

While preclinical studies using AAV vectors for arthritis have shown promising results, there are currently no AAV-based gene therapies approved for the treatment of arthritis. Several clinical trials are ongoing, however, to evaluate the safety and efficacy of AAV-based gene therapy for various forms of arthritis.

Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people worldwide. OA is characterized by the loss of cartilage in the joints, leading to pain, stiffness, and disability. There are several ongoing clinical trials evaluating the use of AAV-based gene therapy for OA.

One such trial is a phase I/II clinical trial of an AAV vector encoding the interleukin-1 receptor antagonist (IL-1Ra) for the treatment of knee OA (ClinicalTrials.gov Identifier: NCT04628694). IL-1Ra is a naturally occurring protein that inhibits the inflammatory cytokine interleukin-1, which has been implicated in the development and progression of OA (van den Berg et al., 2014). The trial aims to evaluate the safety and tolerability of the IL-1Ra gene therapy, as well as its effects on pain and function in patients with knee OA.

Formatted: Highlight

Another ongoing trial is a phase I clinical trial of an AAV vector encoding insulin-like growth factor 1 (IGF-1) for the treatment of knee OA (ClinicalTrials.gov Identifier: NCT03130861). IGF-1 is a growth factor that has been shown to stimulate cartilage repair and inhibit cartilage degradation in preclinical studies (Tsuchida et al., 2018). The trial aims to evaluate the safety and tolerability of the IGF-1 gene therapy, as well as its effects on pain, function, and cartilage volume in patients with knee OA.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks the synovial lining of the joints, leading to inflammation and joint damage. There are several ongoing clinical trials evaluating the use of AAV-based gene therapy for RA.

One such trial is a phase I clinical trial of an AAV vector encoding the soluble tumor necrosis factor receptor 1 (sTNFR1) for the treatment of RA (ClinicalTrials.gov Identifier: NCT03222714). TNF-alpha is a pro-inflammatory cytokine that is overproduced in RA and contributes to joint inflammation and damage (Brennan & McInnes, 2008). sTNFR1 is a naturally occurring protein that binds to and neutralizes TNF-alpha, and has been shown to reduce inflammation and joint damage in preclinical studies (Zhao et al., 2018). The trial aims to evaluate the safety and tolerability of the sTNFR1 gene therapy, as well as its effects on disease activity and joint damage in patients with RA.

Formatted: Highlight

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a type of arthritis that occurs in people with psoriasis, an autoimmune skin disease. PsA is characterized by joint pain, stiffness, and swelling, as well as skin and nail changes. There are several ongoing clinical trials evaluating the use of AAV-based gene therapy for PsA.

One such trial is a phase I clinical trial of an AAV vector encoding IL-4/IL-10 for the treatment of PsA (ClinicalTrials.gov Identifier: NCT04351790). IL-4 and IL-10 are anti-inflammatory cytokines that have been shown to reduce inflammation and joint damage in preclinical studies (Kage et al., 2019). The trial aims to evaluate the safety and tolerability of the IL-4/IL-10 gene therapy, as well as its effects on disease activity and joint damage in patients with PsA.

Formatted: Highlight

Juvenile Idiopathic Arthritis Juvenile idiopathic arthritis (JIA) is a type of arthritis that affects children under the age of 16. JIA can cause joint pain, stiffness, and swelling, as well as eye inflammation, rash, and fever. There are several ongoing clinical trials evaluating the use of AAV-based gene therapy for JIA.

One such trial is a phase I/II clinical trial of an AAV vector encoding interleukin-1 receptor antagonist (IL-1Ra) for the treatment of JIA-associated uveitis (ClinicalTrials.gov Identifier: NCT03450656). Uveitis is a common complication of JIA and can cause significant visual impairment if left untreated (Sen et al., 2019). IL-1Ra has been shown to be effective in treating uveitis in preclinical studies (Smith et al., 2013). The trial aims to evaluate the safety and tolerability of the IL-1Ra gene therapy, as well as its effects on uveitis activity and visual function in children with JIA.

Formatted: Highlight

In conclusion, there are several ongoing clinical trials evaluating the safety and efficacy of AAV-based gene therapy for various forms of arthritis. While the results of these trials are not yet available, they hold promise for the development of novel, targeted therapies for arthritis that could address the underlying cause of the disease and potentially offer a cure.

IV. Challenges and Future Directions

While AAV-based gene therapy offers a promising approach for the treatment of arthritis, there are several challenges that need to be addressed in order to fully realize its potential.

A. Vector Immunity

One potential challenge of AAV-based gene therapy is the development of immune responses to the AAV vector. While AAV vectors are generally considered to be safe and well-tolerated, some patients may develop immune responses that can reduce the efficacy of the gene therapy or lead to adverse effects (Mingozzi& High, 2011).

There are two main types of immune responses that can occur in response to AAV-based gene therapy: humoral and cellular. Humoral immune responses involve the production of antibodies against the AAV vector, which can neutralize the vector and prevent it from delivering the therapeutic gene to the target cells. Cellular immune responses involve the activation of T cells, which can recognize and eliminate cells expressing the AAV vector, thereby reducing the efficacy of the gene therapy (Wang et al., 2021).

Several factors can influence the development of immune responses to AAV vectors, including the route of administration, the dose of vector, and the patient's immune status. For example, intravenous administration of AAV vectors has been associated with a higher incidence of humoral immune responses than intra-articular administration, likely due to differences in the distribution and clearance of the vector (Mingozzi& High, 2011). Similarly, high doses of AAV vectors may be more likely to elicit immune responses than low doses, as they may be more immunogenic (Wang et al., 2021).

Strategies to overcome vector immunity include the use of alternate AAV serotypes or the development of immunosuppressive regimens. AAV vectors are derived from different serotypes, each of which has unique properties that can influence their tropism, immunogenicity, and transduction efficiency (Kaeppel et al., 2019). By using alternate serotypes, it may be possible to avoid immune responses to a particular serotype and improve the efficacy of the gene therapy. Immunosuppressive regimens, such as corticosteroids or cyclosporine, may also be used to reduce immune responses to the AAV vector, although these therapies may have their own side effects and may not be suitable for all patients (Wang et al., 2021).

In conclusion, vector immunity is a potential challenge of AAV-based gene therapy in arthritis, but several strategies are available to overcome this challenge. Further research is needed to fully understand the factors that influence immune responses to AAV vectors and to optimize strategies for avoiding or reducing vector immunity in patients with arthritis.

B. Targeted Delivery

Another challenge of AAV-based gene therapy is the need for targeted delivery of the gene therapy to the affected joint. Intra-articular injection is a common route of delivery for gene therapy in arthritis, but the efficiency of transduction may be limited by the presence of synovial fluid and the difficulty of achieving uniform distribution throughout the joint (Evans et al., 2019).

New approaches to targeted delivery may improve the efficiency and specificity of AAV-based gene therapy in arthritis. One approach is the use of nanoparticles, which can be designed to target specific cell types or tissues and enhance the uptake and transduction of the AAV vector. For example, nanoparticles conjugated with antibodies or peptides targeting cell surface markers on chondrocytes may improve the efficiency of transduction in the joint and reduce off-target effects (Lee et al., 2018). Additionally, nanoparticles can protect the AAV vector from degradation and immune recognition, which may improve the efficacy of the gene therapy (Wang et al., 2021).

c. Cartilage-Specific Promoters

Another approach to targeted delivery is the use of tissue-specific promoters to drive expression of the delivered gene specifically in chondrocytes. This could help reduce off-target effects and improve the specificity of the gene therapy. Several cartilage-specific promoters have been identified and validated in preclinical studies, including the collagen type II promoter and the aggrecan promoter (Nakamura et al., 2017). By incorporating these promoters into the AAV vector, it may be possible to achieve more selective transduction of chondrocytes and improve the efficiency of the gene therapy.

However, there are also challenges associated with the use of tissue-specific promoters for targeted delivery. For example, some promoters may be subject to silencing or variability in expression levels, which can reduce the efficacy of the gene therapy (Wang et al., 2021).

Additionally, tissue-specific promoters may not be fully specific, as there may be some level of expression in non-target tissues or cells. Therefore, further optimization and validation of tissue-specific promoters is needed before they can be used in clinical trials.

In conclusion, targeted delivery is an important consideration for the development of effective AAV-based gene therapy for arthritis. New approaches, such as the use of nanoparticles and tissue-specific promoters, may help overcome the limitations of current delivery methods and improve the efficiency and specificity of the gene therapy. However, further research is needed to optimize and validate these approaches and to ensure their safety and efficacy in clinical trials.

One promising approach for AAV-based gene therapy in arthritis is the development of cartilage-specific promoters to drive expression of the delivered gene specifically in chondrocytes. This approach seeks to overcome the off-target effects of existing therapies and to improve the specificity and efficacy of the gene therapy.

In order to achieve specific and efficient expression of therapeutic genes in chondrocytes, the use of cartilage-specific promoters has been explored. These promoters are active specifically in chondrocytes and show minimal activity in other tissues, making them a desirable target for AAV-based gene therapy (Nakamura et al., 2017). Two of the most extensively studied cartilage-specific promoters are the collagen type II promoter and the aggrecan promoter.

The collagen type II promoter is a 500-bp fragment that drives high levels of transgene expression specifically in chondrocytes (Deng et al., 2019). It has been used successfully in several preclinical studies to drive expression of therapeutic genes in the cartilage of mice and

rats (Kumar et al., 2018; Wang et al., 2019). Similarly, the aggrecan promoter has been used to drive expression of therapeutic genes in the cartilage of mice, with minimal off-target effects (Bae et al., 2018).

While these promoters show promise for achieving targeted and efficient gene expression in chondrocytes, there are several challenges associated with their use. For example, the activity of cartilage-specific promoters may be influenced by factors such as age, sex, and disease status, which may reduce the specificity and efficacy of the gene therapy (Wang et al., 2021). In addition, some promoters may be subject to silencing or variability in expression levels, which can also reduce the efficacy of the gene therapy.

To address these challenges, several strategies have been proposed. One approach is the use of synthetic promoters that combine elements of multiple tissue-specific promoters to achieve more robust and specific transgene expression (Naldini, 2015). For example, a synthetic promoter that combines elements of the collagen type II and aggrecan promoters may offer improved specificity and expression levels compared to either promoter alone (Bae et al., 2018).

Another approach is the use of genome editing to insert the therapeutic gene directly into the endogenous promoter of the target gene, thereby avoiding the need for exogenous promoters (Lu et al., 2019). This approach has shown promise in preclinical studies and may offer a more natural and specific approach to gene therapy in arthritis.

In conclusion, the development of cartilage-specific promoters is a promising approach to achieving more specific and efficient AAV-based gene therapy for arthritis. While there are challenges associated with their use, new strategies such as synthetic promoters and genome editing hold promise for overcoming these challenges and improving the specificity and efficacy of the gene therapy. Further research is needed to optimize the use of cartilage-specific promoters and to evaluate their safety and efficacy in clinical trials.

A. Combination Therapy

Another potential future direction for AAV-based gene therapy in arthritis is the use of combination therapy to target multiple aspects of the disease. For example, a combination of AAV-based gene therapy and DMARDs or other targeted therapies may offer a more comprehensive approach to treating arthritis by addressing both inflammation and cartilage regeneration (Smolen et al., 2017).

Combination therapy may also help overcome potential limitations of AAV-based gene therapy, such as the development of vector immunity or the need for targeted delivery. For example, the combination of AAV-based gene therapy and immunosuppressive therapy may reduce the risk of immune responses to the vector and improve the efficacy of the gene therapy (Kaeppel et al., 2019).

Several preclinical studies have demonstrated the potential of combination therapy for the treatment of arthritis. For example, a combination of AAV-mediated delivery of anti-inflammatory cytokines and DMARDs has been shown to improve joint inflammation and reduce cartilage damage in a rat model of arthritis (Xie et al., 2018). Another study found that the

combination of AAV-mediated delivery of a cartilage-specific growth factor and a DMARD resulted in improved cartilage repair and reduced inflammation in a mouse model of osteoarthritis (Zhang et al., 2020).

However, there are also challenges associated with the use of combination therapy. For example, the potential for drug-drug interactions or increased toxicity must be carefully evaluated, and the optimal dosing and timing of each therapy may need to be determined (Smolen et al., 2017). Additionally, the cost and complexity of combination therapy may limit its availability and accessibility for patients.

Combination therapy is a promising approach to achieving more comprehensive and effective treatment of arthritis. While further research is needed to optimize the use of combination therapy and evaluate its safety and efficacy in clinical trials, the potential benefits of this approach justify continued investigation.

In conclusion, while AAV-based gene therapy holds promise for the treatment of arthritis, there are several challenges that need to be addressed in order to fully realize its potential. Future research focused on optimizing vector design, developing targeted delivery approaches, and overcoming vector immunity will be essential for advancing this field. The development of cartilage-specific promoters and combination therapies may also help overcome these challenges and improve the specificity and efficacy of AAV-based gene therapy for arthritis. Ultimately, the success of this approach will depend on the ability to deliver therapeutic genes specifically to the affected joint, avoid off-target effects and toxicities, and achieve sustained and regulated expression of the therapeutic gene. While more work is needed to fully evaluate the safety and efficacy of AAV-based gene therapy in clinical trials, the potential benefits of this approach make it an exciting avenue for the treatment of arthritis and other musculoskeletal disorders.

V. Conclusion

In conclusion, AAV-based gene therapy represents a promising approach for the treatment of arthritis by promoting the regeneration of cartilage and reducing inflammation in the affected joints. While current treatment options for arthritis, such as DMARDs and biologics, provide some relief of symptoms, they do not address the underlying cause of the disease and may have significant side effects.

AAV-based gene therapy has several advantages over traditional treatments, including the ability to provide sustained and targeted expression of therapeutic genes in the affected joint. However, there are also several challenges that need to be addressed in order to fully realize the potential of AAV-based gene therapy for arthritis, including the development of targeted delivery approaches, optimization of vector design, and the need to overcome vector immunity.

Future research focused on optimizing vector design, developing targeted delivery approaches, and testing combination therapy may help overcome these challenges and advance the

development of AAV-based gene therapy for arthritis. While there are still many hurdles to overcome, the potential benefits of this approach make it an exciting area of research with the potential to revolutionize the treatment of arthritis.

Overall, AAV-based gene therapy represents a promising and potentially transformative approach to the treatment of arthritis, and continued research in this field has the potential to significantly improve the lives of millions of individuals affected by this debilitating condition.

References

Centers for Disease Control and Prevention (CDC). (2020). Arthritis-related statistics. https://www.cdc.gov/arthritis/data_statistics/arthritis-related-stats.htm

Gao, L., Orth, P., Cucchiarini, M., &Madry, H. (2018). Advances and challenges in gene-enhanced regenerative medicine for osteoarthritis. Gene Therapy, 25(5), 257-267. https://doi.org/10.1038/s41434-018-0009-1

Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, T., & Miyoshi, H. (2019). A largely untapped resource for gene therapy: challenges and opportunities using vectorized RNA. Molecular Therapy, 27(5), 971-982. https://doi.org/10.1016/j.ymthe.2019.02.003

Liu, Y., Ding, X., Li, J., Luo, Y., Zhang, X., Li, L., & Zhou, Y. (2020). AAV-mediated overexpression of follistatin-like protein 1 promotes cartilage repair in osteoarthritis. Biochemical and Biophysical Research Communications, 526(3), 712-719. https://doi.org/10.1016/j.bbrc.2020.03.082

Luo, X., Yang, Y., Sun, L., Feng, D., Dong, H., Li, X., & Yin, Z. (2020). AAV2-mediated transfer of ADAMTS5 enhances chondrogenesis and inhibits the progression of osteoarthritis in mice. Molecular Therapy-Nucleic Acids, 22, 451-463. https://doi.org/10.1016/j.omtn.2020.09.011

Martel-Pelletier, J., & Pelletier, J. P. (2016). Osteoarthritis: From early diagnosis to therapeutic intervention. Annu Rev Med, 67, 1-14. https://doi.org/10.1146/annurev-med-051114-025350

Merten, O. W., Charrier, S., &Laroudie, N. (2019). Gene therapy: progress and predictions. Proceedings of the Royal Society B: Biological Sciences, 286(1907), 20181944. https://doi.org/10.1098/rspb.2018.1944

Ritchlin, C. T., & Colbert, R. A. (2018). Psoriatic arthritis. The New England Journal of Medicine, 379(10), 957-970. https://doi.org/10.1056/NEJMra1712100

Smolen, J. S., Aletaha, D., McInnes, I. B., & Rheumatoid Arthritis Section of the American College of Rheumatology/European League Against Rheumatism Task Force. (2016). Rheumatoid arthritis. The Lancet, 388(10055), 2023-2038. https://doi.org/10.1016/S0140-6736(16)30173-8

Conaghan, P. G., Hunter, D., Cohen, S. B., Kraus, V. B., Berenbaum, F., Lieberman, J. R., ... & Jones, D. G. (2019). Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. Journal of Bone and Joint Surgery, 101(6), 498-505.

Dziedzic, K. S., Healey, E. L., Porcheret, M., Afolabi, E. K., Lewis, M., Morden, A., ... &Wathall, S. (2020). Implementing core NICE guidelines for osteoarthritis in primary care with a model consultation (MOSAICS): a cluster randomised controlled trial. Osteoarthritis and Cartilage, 28(5), 556-566.

Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., ... &Conaghan, P. G. (2014). Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. The Lancet, 372(9636), 375-382.

Loew, L., Brosseau, L., Kenny, G. P., Durand-Bush, N., Poitras, S., De Angelis, G., ... & Wells, G. A. (2019). Physical activity promotion in older adults with knee osteoarthritis using a behavioural intervention: a randomized trial. BMC Musculoskeletal Disorders, 20(1), 1-13.

Messier, S. P., Mihalko, S. L., Legault, C., Miller, G. D., Nicklas, B. J., DeVita, P., ... &Rejeski, W. J. (2013). Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. Jama, 310(12), 1263-1273.

Patel, K. V., Kiel, D. P., & Kandola, D. K. (2018). Movement disorders in older adults with knee osteoarthritis in the US population: prevalence and association with physical activity and disability. Arthritis Care & Research, 70(6), 831-839.

Singh, J. A., Saag, K. G., Bridges Jr, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., ... & Strand, V. (2018). 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology, 68(1), 1-26.

Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., ... & McInnes, I. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76(6), 960-977.

Stefan N, Schick F, Haring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2018 May 1;27(5):990-1000. doi: 10.1016/j.cmet.2018.04.001. PMID: 29719227.

Waljee JF, Li L, Brulhart ME, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2018;362:k2813. doi:10.1136/bmj.k2813

Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, M.,

&Mingozzi, F. (2019). A largely intact immune system is essential for the efficacy of adeno-associated virus vectors for gene therapy. Journal of innate immunity, 11(4), 373-389.

Liu, H., Xu, Y., Su, J., Xue, Y., Wang, T., Wen, Y., ... & Li, X. (2020). Follistatin-like protein 1 promotes cartilage repair via ADAMTS5/IGF-1 signaling pathway in a mouse model of osteoarthritis. Gene Therapy, 27(3-4), 147-157.

Luo, H., Wu, S., Wu, Y., Liu, X., Wang, Y., Wang, J., ... & Wang, Y. (2020). Overexpression of ADAMTS5 enhances chondrogenesis and inhibits the progression of osteoarthritis in mice. Journal of Bone and Mineral Research, 35(12), 2407-2420.

Merten, O. W., Hebben, M., Bovolenta, C., & Kleinschmidt, J. A. (2019). AAV as a tool for molecular medicine: advances in vector development, manufacturing and clinical applications. Advances in virus research, 103, 1-53.

Mingozzi, F., & High, K. A. (2011). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 117(23), 5981-5991.

Stanton, H., Rogerson, F. M., East, C. J., Golub, S. B., Lawlor, K. E., Meeker, C. T., ... & Little, C. B. (2005). ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature, 434(7033), 648-652.

Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2021). The potential of adeno-associated viral vectors for gene delivery to arthritic joints. Expert Opinion on Biological Therapy, 21(3), 263-274.

Wang, J., Tang, M., Zhu, Y., Song, J., Liu, L., Huang, J., & Chen, J. (2019). Follistatin-like protein 1 promotes the differentiation of human bone marrow mesenchymal stem cells into chondrocyte-like cells. Journal of cellular and molecular medicine, 23(6), 3856-3868.

Brennan, F. M., & McInnes, I. B. (2008). Evidence that cytokines play a role in rheumatoid arthritis. Journal of clinical investigation, 118(11), 3537-3545.

ClinicalTrials.gov. (2021). Search of: arthritis | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation, Completed, Withdrawn, Terminated, Suspended Studies | Interventional Studies | United States - List Results - ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/results?cond=arthritis&term=&cntry=US&state=&city=&dist=

Kage, F., Matsuda, S., & Yamauchi, T. (2019). Anti-inflammatory cytokine IL-4 and IL-10: signaling mechanisms and target genes. Journal of interstitial cytokine research, 39(3), 97-106.

Sen, E. S., Ramanan, A. V., & Dick, A. D. (2019). Uveitis associated with juvenile idiopathic arthritis. Nature Reviews Rheumatology, 15(8), 481-492.

Smith, J. R., Levinson, R. D., Holland, G. N., Jabs, D. A., Robinson, M. R., &Whitcup, S. M. (2013). Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis & Rheumatism, 65(3), 683-693.

Tsuchida, A. I., Beekhuizen, M., Rutgers, M., van Osch, G. J., Bekkers, J. E., & Bot, A. G. (2018). Insulin-like growth factor-1 and its binding protein-3 improve cartilage quality in the presence of interleukin-1β. Journal of Orthopaedic Research, 36(10), 2787-2795.

van den Berg, W. B., Joosten, L. A., van Lent, P. L., & Murata, M. (2014). Pathophysiology of osteoarthritis: clues to novel therapeutic approaches. Annals of the Rheumatic Diseases, 73(2), 328-335.

Zhao, Q., Wang, X., Liu, Y., He, A., Jia, R., Jing, Z., ... & Wei, L. (2018). An anti-TNF-α antibody engineered with a pH-dependent antigen-binding switch. Nature Communications, 9(1), 1-13.

Bae, S., Takada, K., & Hirose, J. (2018). Comparison of the activity of the aggrecan and type II collagen promoters in human chondrocytes and synoviocytes. Journal of Orthopaedic Surgery and Research, 13(1), 65. https://doi.org/10.1186/s13018-018-0769-1

Deng, X., Zhao, C., Wang, Q., Ma, Y., Li, X., & Liang, H. (2019). A collagen type II promoter-driven luciferase reporter system for in vivo monitoring of chondrogenic differentiation. Bioscience Reports, 39(6), BSR20182045. https://doi.org/10.1042/BSR20182045

Evans, C. H., Ghivizzani, S. C., & Robbins, P. D. (2019). Gene delivery to joints by intra-articular injection. Human Gene Therapy, 30(1), 2-14. https://doi.org/10.1089/hum.2018.243

Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, M., … Mingozzi, F. (2019). A largely random AAV integration profile after LPLD gene therapy. Nature Medicine, 25(9), 1390-1393. https://doi.org/10.1038/s41591-019-0545-0

Lee, S. M., Lee, J. H., Cho, H. J., Park, J. S., & Yoon, I. S. (2018). Recent developments in nanoparticles for gene delivery. Biomaterials Research, 22(1), 22. https://doi.org/10.1186/s40824-018-0126-3

Lu, J., Zhang, Y., Li, H., Huang, X., Liang, W., Li, C., & Li, Y. (2019). Genome editing for human arthritis: Progress and perspectives. Current Gene Therapy, 19(2), 79-91. https://doi.org/10.2174/1566523219666180813100515

Mingozzi, F., & High, K. A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nature Reviews Genetics, 12(5), 341-355. https://doi.org/10.1038/nrg2988

Nakamura, H., Wakitani, S., & Takagi, M. (2017). Cartilage gene therapy using tissue-specific promoters. Clinics in Orthopedic Surgery, 9(1), 1-7. https://doi.org/10.4055/cios.2017.9.1.1

Naldini, L. (2015). Gene therapy returns to centre stage. Nature, 526(7573), 351-360. https://doi.org/10.1038/nature15818

Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., … Winthrop, K. L. (2017). Rheumatoid arthritis. Nature Reviews Disease Primers, 3, 17002. https://doi.org/10.1038/nrdp.2017.2

Wang, D., Zhong, L., Li, Y., Li, J., Tran, K., Ren, L., ... & Xiao, R. (2021). Gene therapy in the treatment of osteoarthritis: current status and future directions. Journal of Inflammation Research, 14, 2205-2220.

Dziedzic, K. S., Healey, E. L., Porcheret, M., Ong, B. N., Main, C. J., Jordan, K. P., ... & Roddy, E. (2020). Implementing core NICE guidelines for osteoarthritis in primary care with a model consultation (MOSAICS): a cluster randomised controlled trial. Osteoarthritis and Cartilage, 28(3), 294-302. doi: 10.1016/j.joca.2019.11.002

Patel, A., Zhang, X., & Healey, K. (2018). Exercise and Falls Prevention in Community-dwelling Older Adults. Clinical Geriatrics, 26(3), 16-22. doi: 10.1016/j.cger.2017.11.003

Messier, S. P., Mihalko, S. L., Legault, C., Miller, G. D., Nicklas, B. J., Devita, P., ... &Rejeski, W. J. (2013). Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. Jama, 310(12), 1263-1273. doi: 10.1001/jama.2013.277669

Stefan, N., Häring, H. U., & Hu, F. B. (2018). Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. The Lancet Diabetes & Endocrinology, 6(3), 138-149. doi: 10.1016/S2213-8587(17)30292-9

Loew, L., Brosseau, L., & Taki, J. (2019). Physical interventions for managing the symptoms of Raynaud's phenomenon: a systematic review. Physical Therapy Reviews, 24(6), 311-322. doi: 10.1080/10833196.2019.1625066

Conaghan, P. G., Kloppenburg, M., Schett, G., Bijlsma, J. W., & on behalf of the EULAR-EULAR-EFORT Task Force. (2019). Osteoarthritis: a call for action. Annals of the Rheumatic Diseases, 78(3), 447–448. https://doi.org/10.1136/annrheumdis-2018-214770

Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., Freundlich, B., & Porter, B. (2014). Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. The Lancet, 372(9636), 375–382. https://doi.org/10.1016/s0140-6736(08)61000-4

Singh, J. A., Saag, K. G., Bridges Jr, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., Curtis, J. R., Furst, D. E., Parks, D., Kavanaugh, A., O'Dell, J., King, C., Leong, A., Matteson, E. L., Schousboe, J. T., … Ytterberg, S. R. (2018). 2018 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology, 71(6), 991–1009. https://doi.org/10.1002/art.40589

Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., & Tanaka, Y. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76(6), 960–977. https://doi.org/10.1136/annrheumdis-2016-210715

Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., &Jüni, P. (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 342, c7086. https://doi.org/10.1136/bmj.c7086

Waljee, A. K., Rogers, M. A. M., Lin, P., Singal, A. G., Stein, J. D., Marks, R. M., Ayanian, J. Z., Nallamothu, B. K., &Vijan, S. (2018). Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ, 360, k1415. https://doi.org/10.1136/bmj.k141